BioElectronics Completes Menstrual Pain Clinical Study
Thursday, December 31st, 2009BioElectronics Corp. (PINKSHEETS: BIEL), the maker of economical, disposable hallucinogenic-self-governed anti-inflammatory devices, announced its clinical study on the use of Allay™ Therapy with a view the treatment of menstrual soreness and cramping (primary dysmenorrhea) pleasure conclude on May 8. BioElectronics intends to folder 510(K) premarket notification for the data of reducing menstrual agony symptoms with the U.S. Food and Medicine Charge by the stop of May.
“Participants were recruited quicker than we had initially expected, allowing us to group our data a month vanguard of schedule,” commented Barry Eppley, M.D., D.M.D., the study’s primary investigator. “There has been a huge amount of enthusiasm about our research; many more women than we needed requested participation. The study’s results will be published over the next not many weeks.”
Andrew Whelan, CEO of BioElectronics Corp., commented, “Between 60 and 70 percent of women suffer from pain during menstruation, with millions of women experiencing pain severe enough to restrict their daily activities. BioElectronics believes a multimillion dollar market exists for the treatment of primary dysmenorrhea. Our version of PEMF remedy offers strong bid fair through despite the reduction or alleviation of such vexation.”
The Allay study was conducted by Dr. Barry Eppley, of Indianapolis, Indiana and Dr. Sheena Kong, of San Francisco, California.
In the initial pilot bone up on, which was released during October of 2008, 23 female patients (ages 19 to 37) with problematic menstrual issues used the Allay Time continuously for five days following the beginning of their menstrual period. The women rated their pain over this at intervals frame using the same 1-10 pain scale that they had used during a authority over days. During the control period, the commonplace composite pain rating was 7.8 with mediocre every day composite pain ratings from hour equal to five at 8.3, 7.9, 7.4, 6.5 and 5.7, severally. During the Allay treatment sessions the normally composite pain rating was only 5.4, with average daily composite pain ratings of 5.7, 4.8, 4.3, 3.4, and 2.1. This correlates to total misery reduction on a daily point of departure of 31 percent, 39 percent, 42 percent, 48 percent and 73 percent respectively.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch® Analysis, RecoveryRx™ Devices, HealFast™ Remedy (http://www.healfasttherapy.com) and Allay™ kith and kin of inexpensive, non-returnable anaesthetize-free anti-insurgent devices. These devices utilize embedded battery operated microchips to bear weeks of bailiwick treatment for solely about a dollar a day. The unparalleled delivery method, using patented technology, provides a cost shit patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by salubrity Canada for the comfort of pain and musculoskeletal complaints. The US superintendence scoff and dope administration (FDA) has cleared the use of the consequence for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a Stratum II pulsed electromagnetic medical monogram as maintain numerous other international agencies. For more information please see http://www.BioElectronicsCorp.com.
Riskless Harbor Statement
This news release contains forward-looking statements coordinated to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of simultaneous conditions, expected tomorrow developments and other factors it believes to be apropos. Existing results may differ as a result of factors over which the company has no control.
Source
BioElectronics Corporation